RxDoctor Payments Data

Rosa Young, PA

Physician Assistant · Moore, OKNPI 1730755265

Payments from drug & device makers

$1,615in general payments, 2019–2025

Across 44 payments — averaging $36.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • AstraZeneca$270
  • Biohaven Pharmaceuticals, Inc.$200
  • Kyowa Kirin, Inc.$122
  • Grifols USA, LLC$117
  • Jazz Pharmaceuticals Inc.$113
  • plus $474 from 14 others

What the payments were for

  • Food & beverage$1,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615 in reported general payments places this provider in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$50,388
Medicare patients
244
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate58$96,805
RytaryCarbidopa/Levodopa51$79,971
Emgality PenGalcanezumab-Gnlm86$75,625
Ajovy AutoinjectorFremanezumab-Vfrm49$51,580
QuliptaAtogepant35$51,029
Aimovig AutoinjectorErenumab-Aooe49$37,211
Emgality SyringeGalcanezumab-Gnlm30$23,924
UbrelvyUbrogepant17$21,757
ReyvowLasmiditan Succinate11$7,928
Gabapentin155$3,492
Carbidopa-LevodopaCarbidopa/Levodopa120$3,179
Oxcarbazepine37$3,173
Duloxetine Hcl104$2,961
Amitriptyline Hcl98$1,454
Primidone37$1,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$17$96,80558 claims
AbbVieQulipta, Ubrelvy$319$72,78652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Moore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →